Mineralys Therapeutics to Present Lorundrostat Data at AHA Hypertension Sessions

Mineralys Therapeutics, Inc. will present data on its lorundrostat drug at the American Heart Association Hypertension Scientific Sessions in 2026. The company is developing medicines targeting hypertension and aldosterone-related outcomes in conditions like chronic kidney disease and obstructive sleep apnea.